SecBot SecBot
8-K ·Filed Nov 4, 2026

URGN

UroGen Pharma Ltd.
NEUTRAL
Impact 5/10
Horizonmonths Processed12d 18h ago SEC0001437749-26-034769
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

ZUSDURI's 35% QoQ growth and narrowing net loss signal strong commercial execution, but the JELMYTO guidance cut and cash burn ($17.5M QoQ decline in cash) temper the positive read. The UGN-103 PDUFA in June 2027 is the next major catalyst; monitor 12-month DOR data submission during the review.

DirectionNeutral
Confidencehigh
Horizonmonths

Price Chart

Loading chart...

Executive Summary

UroGen reported Q3 2026 total revenue of $89.0M, up from $27.5M a year ago, driven by ZUSDURI net product revenue of $68.0M (35% QoQ growth). Net loss narrowed to $1.5M ($0.03/share) from $33.3M ($0.69/share) in Q3 2025. The company lowered its full-year 2026 JELMYTO revenue guidance to approximately $90M from $97M-$101M, citing a one-time CMS gross-to-net adjustment and competitive trial enrollment headwinds. The FDA accepted the UGN-103 NDA with a PDUFA date of June 14, 2027.

Key Financial Metrics

EPS
−$0.03
Revenue
$89.0M
est $89.9M · -1.0% · +223.8% YoY
Guidance
approximately $90M (JELMYTO only)
lowered
Gross Margin
91.6%

Key Facts

  • ZUSDURI net product revenue of $68.0M in Q3 2026, up 35% from Q2 2026
  • Total revenue of $89.0M in Q3 2026, up from $27.5M in Q3 2025
  • Net loss of $1.5M ($0.03/share) in Q3 2026 vs $33.3M ($0.69/share) in Q3 2025
  • JELMYTO revenue guidance lowered to approximately $90M from $97M-$101M
  • FDA accepted UGN-103 NDA with PDUFA date of June 14, 2027
  • Cash, cash equivalents and marketable securities of $90.5M as of September 30, 2026
  • 1,538 activated sites of care and 662 unique ZUSDURI prescribers as of September 30, 2026
  • 331 repeat ZUSDURI prescribers, approximately 50% of total prescribers

Financial Impact

ZUSDURI revenue $68.0M in Q3 2026, total revenue $89.0M, net loss $1.5M; JELMYTO guidance cut by $7M-$11M to approximately $90M

revenuenet lossguidance

Segment Breakdown

SegmentRevenueGrowth
ZUSDURI$68.0MNot reported
JELMYTO$21.0M-18.3%

Risk Factors

  • JELMYTO revenue guidance lowered to approximately $90M due to CMS true-up and competitive enrollment
  • Cash and marketable securities declined from $108.0M (June 30, 2026) to $90.5M (September 30, 2026)
  • UGN-103 NDA approval not guaranteed; PDUFA date is June 14, 2027
  • Operating expenses expected toward upper end of $260M-$270M range

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001437749-26-034769
Document: urgn20261026_8k.htm0001437749-26-034769
Document: 0001437749-26-034769-index-headers.html0001437749-26-034769
Document: 0001437749-26-034769-index.html0001437749-26-034769
Document: 0001437749-26-034769.txt0001437749-26-034769
8-K Data (Synthetic)0001437749-26-034769

Track record

16 reports on URGN

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +54.89% at T+60 after the Mar 2, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $25.90 Now $28.10 +8.49% settles Nov 23
  2. Nov 4, 202612d ago 8-K Neutral 5/10 Viewing No price data
  3. Nov 4, 202612d ago Press Release Bearish 6/10 Entry $28.74 to $26.10 Now $28.10 +2.23% ▲ +9.19% +8.27% vs SPY
  4. Nov 2, 202614d ago Press Release Neutral 4/10 Entry $34.36 to $26.31 Now $28.10 −18.22% ▼ −23.43% −23.51% vs SPY
  5. Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $33.75 to $28.74 Now $28.10 −16.74% ▼ −14.84% −14.13% vs SPY
  6. Oct 19, 202628d ago Press Release Bullish 6/10 Entry $34.15 to $34.23 Now $28.10 −17.72% ▲ +0.23% +0.38% vs SPY
  7. Oct 9, 20265w ago 144 Neutral 2/10 Entry $36.83 to $34.56 Now $28.10 −23.70% ▼ −6.16% −4.20% vs SPY
  8. Sep 9, 20269w ago Insider Cluster Neutral 2/10 Entry $45.00 to $43.04 Now $28.10 −37.56% ▼ −4.36% −4.02% vs SPY
  9. Aug 20, 202612w ago 8-K Neutral 4/10 Entry $46.80 to $45.50 Now $28.10 −39.96% ▼ −2.78% −3.89% vs SPY
  10. Aug 5, 202614w ago 8-K Bullish 7/10 Entry $46.43 to $49.00 Now $28.10 −39.48% ▲ +5.54% +5.18% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026